Trade Mind Medicine (MindMed) Inc. Subordinate Voting Shares - MNMD CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.06 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.02354% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001318% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 0.01 | ||||||||
| Currency | USD | ||||||||
| Margin | 50.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 6.4 |
| Open | 6.36 |
| 1-Year Change | -33.05% |
| Day's Range | 6.1 - 6.36 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Mar 28, 2025 | 6.15 | -0.11 | -1.76% | 6.26 | 6.44 | 6.07 |
| Mar 27, 2025 | 6.40 | -0.09 | -1.39% | 6.49 | 6.54 | 6.25 |
| Mar 26, 2025 | 6.54 | -0.07 | -1.06% | 6.61 | 6.75 | 6.39 |
| Mar 25, 2025 | 6.77 | -0.11 | -1.60% | 6.88 | 6.88 | 6.63 |
| Mar 24, 2025 | 6.91 | 0.10 | 1.47% | 6.81 | 7.01 | 6.60 |
| Mar 21, 2025 | 6.69 | 0.22 | 3.40% | 6.47 | 6.81 | 6.45 |
| Mar 20, 2025 | 6.63 | 0.07 | 1.07% | 6.56 | 6.82 | 6.48 |
| Mar 19, 2025 | 6.68 | 0.32 | 5.03% | 6.36 | 6.72 | 6.31 |
| Mar 18, 2025 | 6.39 | 0.13 | 2.08% | 6.26 | 6.46 | 6.18 |
| Mar 17, 2025 | 6.44 | 0.13 | 2.06% | 6.31 | 6.52 | 6.21 |
| Mar 14, 2025 | 6.29 | -0.03 | -0.47% | 6.32 | 6.49 | 6.19 |
| Mar 13, 2025 | 6.27 | -0.06 | -0.95% | 6.33 | 6.55 | 6.26 |
| Mar 12, 2025 | 6.41 | 0.00 | 0.00% | 6.41 | 6.74 | 6.39 |
| Mar 11, 2025 | 6.30 | 0.03 | 0.48% | 6.27 | 6.51 | 5.92 |
| Mar 10, 2025 | 6.28 | -0.24 | -3.68% | 6.52 | 6.53 | 6.07 |
| Mar 7, 2025 | 6.78 | 0.33 | 5.12% | 6.45 | 6.89 | 6.45 |
| Mar 6, 2025 | 6.55 | 0.64 | 10.83% | 5.91 | 6.78 | 5.91 |
| Mar 5, 2025 | 6.37 | 0.18 | 2.91% | 6.19 | 6.38 | 5.89 |
| Mar 4, 2025 | 6.23 | 0.26 | 4.36% | 5.97 | 6.25 | 5.74 |
| Mar 3, 2025 | 6.02 | -0.75 | -11.08% | 6.77 | 6.77 | 6.00 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 20
- 100
- 500
- 1000
- 10000
Mind Medicine (MindMed) Company profile
Mind Medicine (MindMed) Inc is a biopharmaceutical company that develops clinical-stage psychedelic medicines to treat brain health disorders. The New York-based firm specialises in psychiatry, addiction, pain management and neurology.
Founded in May 2019, MindMed has several drug candidates targeting serotonin, dopamine and acetylcholine systems. These products are based on psychedelic and empathogen substances. The company’s main drug candidate is MM-120, which is a proprietary, pharmaceutically optimised form of LSD. The medication is being developed to treat generalised anxiety disorder (GAD). MindMed is also researching the drug in various dosing regimens for the treatment of attention deficit hyperactivity disorder, also known as attention-deficit/hyperactivity disorder (ADHD), as well as chronic pain.
MM-110, the company’s second advanced drug, is being developed to treat opioid withdrawal. The MM-110, also known by the non-proprietary name zolunicant, is a form of 18-methoxycoronaridine, an ibogaine congener.
The company’s third medicine candidate is MM-402, or R(-)-MDMA, a proprietary form of the R-enantiomer of MDMA (3,4-methylenedioxymethamphetamine). The medicine is being developed for the treatment of core symptoms of autism spectrum disorder.
In addition to its advanced stage drugs, the company also has several earlier stage research programmes through external collaboration, including a multi-year exclusive partnership with University Hospital Basel (UHB) in Switzerland.
MindMed does not own or operate any manufacturing facilities. All clinical and non-clinical materials are supplied by third-party contract manufacturing organisations, or CMOs.
MindMed went public on 27 February 2020 on the Toronto-based NEO Exchange under the ticker ‘MMED’. It is listed on Nasdaq under the symbol ‘MNMD’ and in Germany under the ticker ‘BGHM’.
| Industry: | Biotechnology & Medical Research (NEC) |
One World Trade Center
Suite 8500
NEW YORK
NEW YORK 10007
US
News
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025
Coffee price forecast: 2025-2030 third-party coffee target
Coffee prices have cooled considerably in the past few months. Is a rebound in store or will they continue to fall?
09:42, 12 March 2025
The Simpsons predicted XRP to hit $589: Has the show got it right again?
Did the animated TV show predict a breakout for the XRP cryptocurrency?
11:00, 11 March 2025
Rolls-Royce share price forecast: third- party price target
Our Rolls-Royce share price forecast looks at the outlook for the FTSE 100-listed engineering company after a tough few years.
14:58, 10 March 2025
Gasoline petrol price forecast 2025-2030: Third-party price target
Discover third-party gasoline (petrol) price predictions for 2025 and beyond, with analyst targets, historical prices, and trading strategies.
10:27, 3 March 2025
USD forecast - third party data round up
The DXY hit a seven-month low in January, just a few months after a multi-decade peak in late September.
10:02, 27 February 2025
Microsoft Stock Price Forecast for 2025 and beyond: Third party price target
We assess the likely level of the Microsoft stock price in 5 years, and possible drivers behind the stock’s past performance. Read on...
18:29, 7 February 2025People also watch
Still looking for a broker you can trust?
Join the 710,000+ traders worldwide that chose to trade with Capital.com